-

$undefined

N/A

(N/A)

Agenus Inc. NASDAQ:AGEN Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA.

Location: 3 Forbes Rd, Massachusetts, 02421-7305, US | Website: www.agenusbio.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

109.3M

Cash

40.44M

Avg Qtr Burn

-39.58M

Short % of Float

14.44%

Insider Ownership

1.31%

Institutional Own.

33.81%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034) Details Colorectal cancer , Cancer Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Botensilimab (AGEN1181) (anti-CLTA-4) Details Cancer, Pancreatic cancer, Melanoma Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AGEN1777 (BMS-986442) (TIGIT)+ nivolumab and/or chemotherapies Details Cancer, Non-small cell lung carcinoma, Solid tumor/s, Lung cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Botensilimab (AGEN1181) + balstilimab Details Cancer, Sarcoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Botensilimab (AGEN1181) Details Cancer, Non-small cell lung carcinoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034) Details Cancer, Ovarian cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AGEN2373 w/ Botensilimab (AGEN1181) Details Solid tumor/s, Cancer, Melanoma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AGEN1571 w/ Botensilimab (AGEN1181) & Balstilimab (AGEN2034) Details Solid tumor/s, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Balstilimab (AGEN2034) Details Cancer, Cervical cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AGEN1423 (anti-CD73-TGFβ-trap bifunctional antibody) + balstilimab (anti-PD-1) Details Pancreatic cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Balstilimab (anti- PD-1) + Zalifrelimab (anti-CTLA-4) Details Cancer, Cervical cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.